Novel antibody molecule aiming at human CLDN18.2, antigen binding fragment and medical application thereof

A technology for binding fragments and antibody molecules, applied in the direction of anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, medical preparations containing active ingredients, antibodies, etc., can solve the problems of immunogenicity risks and other problems
CN110606891AActive Publication Date: 2019-12-24L&L BIOPHARMA CO LTD
5 Cites 37 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
L&L BIOPHARMA CO LTD
Publication Date
2019-12-24

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an anti-human CLDN18.2 antibody as well as an antigen binding fragment and a medical application thereof. Specifically, the present invention relates to a murine antibody comprising a CDR region of the anti-human CLDN18.2 antibody, a chimeric antibody and a humanized antibody, a fully humanized antibody, an antibody-dependent cytotoxicity (ADCC) comprising the antibody andthe antigen binding fragment thereof, complement dependent cytotoxicity (CDC), the killing effect on CLDN18.2 positive cells, the effect of inhibiting the growth of CLDN18.2 positive tumors, the in-vivo drug effect, a medicine containing the anti-human CLDN18.2 antibody and the antigen binding fragment thereof, a composition of the medicine thereof, and an application of the medicine in tumor treatment, in particular to treatment of CLDN18.2 positive tumor patients..
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a human CLDN18.2 antibody, a CLDN18.2 antigen-binding fragment, a murine antibody comprising the CDR region of the CLDN18.2 antibody, a chimeric antibody composed of a murine antibody variable region and a human antibody constant region, a human Antibody-dependent cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) effects of humanized antibodies, fully humanized antibodies, and antigen-binding fragments thereof. The drug combination comprising the antibody and its antigen-binding fragment, its killing effect on tumor cells, especially CLDN18.2 high expression (CLDN18.2 positive) tumor cells, its pharmacodynamic activity in animals, and its single or drug combination The drug is used as an anticancer drug, especially for the treatment of patients with CLDN18.2 overexpression tumors. Background technique

[0002] Cancer is a great threat to human health and one of the important causes of death in the field ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More